Location: Netherlands (Required)
Work Mode: Remote from the Netherlands with occasional travelling required
Time Commitment: Part-time (approx 50%)
Company Stage: Pre-incorporation, Preclinical
Sector: Oncology Biotech | Cancer Stem Cell Targeting | Drug Development
Compensation: Equity only during pre seed phase; salary post financing
Emerging biotech venture developing a first-in-class therapeutic platform aimed at eradicating cancer stem cells (CSCs) which is a persistent source of relapse and metastasis in many cancers. The lead candidate is a novel protein drug conjugate (PDC), an advanced type of Antibody-Drug Conjugate (ADC)-like that uses a mimic of a natural ligand (R-spondin) to selectively bind to cancer stem cell receptors such as LGR4/5/6, overcoming the limitations of conventional antibody targeting.
The science is based on:
This is a rare opportunity to lead a startup positioned to address a profound unmet need in oncology through scientifically validated innovation.
As CEO, you will lead a highly promising early-stage biotech and lead it from scientific concept to clinical-stage company. Your mission is to:
This role requires vision, operational leadership, and deep appreciation of biotech venture-building. You’ll work closely with NLC (founding party) and the CSO (already appointed), who covers scientific leadership, allowing the CEO to focus on business execution and company growth.
This is a defining role at the helm of a scientifically differentiated biotech startup with a clear therapeutic rationale and significant platform potential. Backed by a committed venture fund and led by a strong scientific team, it offers the right CEO an opportunity to lead a high-impact company at a critical inflection point.
This start-up is being built in collaboration with NLC Health Ventures, Europe’s leading healthtech venture builder. With over 100 ventures created to date, NLC identifies breakthrough innovations, builds expert teams around them, and supports each venture from lab to market. Through hands-on operational guidance, fundraising support, and access to dedicated capital, NLC helps founders turn scientific breakthroughs into investable, scalable companies.
Rapinno Health Care
Yitro Global
Oportun
Palex Medical
Glovo